Metabolites profile of colorectal cancer cells at different stages
Objective: The aim of this study is to characterize the metabolite profiles of colorectal cancer (CRC) cells of different stages of the disease to understand the pathophysiological changes that may help to identify prevention strategies as well as the sites for potential therapeutic drug actions. Me...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Innovare Academics Sciences Pvt. Ltd
2019
|
Subjects: | |
Online Access: | View Fulltext in Publisher View in Scopus |
LEADER | 04105nam a2200817Ia 4500 | ||
---|---|---|---|
001 | 10.22159-ijap.2019.v11s1.T0051 | ||
008 | 220121s2019 CNT 000 0 und d | ||
020 | |a 09757058 (ISSN) | ||
245 | 1 | 0 | |a Metabolites profile of colorectal cancer cells at different stages |
260 | 0 | |b Innovare Academics Sciences Pvt. Ltd |c 2019 | |
650 | 0 | 4 | |a 1,2,4 nonadecanetriol |
650 | 0 | 4 | |a 13 oxo 9 octadecenoic acid |
650 | 0 | 4 | |a 2 methylbutyroylcarnitine |
650 | 0 | 4 | |a acetylcarnitine |
650 | 0 | 4 | |a amillaripin |
650 | 0 | 4 | |a armillaripin |
650 | 0 | 4 | |a Article |
650 | 0 | 4 | |a cancer prevention |
650 | 0 | 4 | |a Cancer stages |
650 | 0 | 4 | |a cancer staging |
650 | 0 | 4 | |a chemical analysis |
650 | 0 | 4 | |a Colorectal cancer |
650 | 0 | 4 | |a colorectal cancer cell line |
650 | 0 | 4 | |a comparative study |
650 | 0 | 4 | |a DLD-1 cell line |
650 | 0 | 4 | |a drug identification |
650 | 0 | 4 | |a drug mechanism |
650 | 0 | 4 | |a flavine adenine nucleotide |
650 | 0 | 4 | |a flavine mononucleotide |
650 | 0 | 4 | |a glucose 6 phosphate |
650 | 0 | 4 | |a HCT 116 cell line |
650 | 0 | 4 | |a HCT 15 cell line |
650 | 0 | 4 | |a hexadeconoic acid |
650 | 0 | 4 | |a HT-29 cell line |
650 | 0 | 4 | |a human |
650 | 0 | 4 | |a human cell |
650 | 0 | 4 | |a lactic acid |
650 | 0 | 4 | |a leucine |
650 | 0 | 4 | |a liquid chromatography-mass spectrometry |
650 | 0 | 4 | |a lumichrome |
650 | 0 | 4 | |a lysope |
650 | 0 | 4 | |a metabolic fingerprinting |
650 | 0 | 4 | |a metabolomics |
650 | 0 | 4 | |a Metabolomics |
650 | 0 | 4 | |a methanol |
650 | 0 | 4 | |a methionine |
650 | 0 | 4 | |a muricatacin |
650 | 0 | 4 | |a palmitic acid |
650 | 0 | 4 | |a pantothenic acid |
650 | 0 | 4 | |a pathophysiology |
650 | 0 | 4 | |a phenylalanine |
650 | 0 | 4 | |a phytosphingosine |
650 | 0 | 4 | |a pipericine |
650 | 0 | 4 | |a protein |
650 | 0 | 4 | |a riboflavin |
650 | 0 | 4 | |a software |
650 | 0 | 4 | |a SW1116 cell line |
650 | 0 | 4 | |a SW480 cell line |
650 | 0 | 4 | |a unclassified drug |
650 | 0 | 4 | |a upregulation |
650 | 0 | 4 | |a water |
856 | |z View Fulltext in Publisher |u https://doi.org/10.22159/ijap.2019.v11s1.T0051 | ||
856 | |z View in Scopus |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073502138&doi=10.22159%2fijap.2019.v11s1.T0051&partnerID=40&md5=a9ed72467b09073178175f9203fc5ad4 | ||
520 | 3 | |a Objective: The aim of this study is to characterize the metabolite profiles of colorectal cancer (CRC) cells of different stages of the disease to understand the pathophysiological changes that may help to identify prevention strategies as well as the sites for potential therapeutic drug actions. Methods: Six CRC cell lines of different stages (classified using the Dukes classification) were used, and they are SW 1116 (stage A), HT 29 and SW 480 (stage B), HCT 15 and DLD-1 (stage C), and HCT 116 (stage D). Metabolites were extracted using methanol and water, and metabolic profiling was performed using liquid chromatography-mass spectrometry. Mass profiler professional software was used for statistical analysis. Results: There were 111,096 compounds detected across the samples, and 24 metabolites were identified to be significantly different between the CRC stages. Most notably, there were eight metabolites that were significantly upregulated in the more advanced stages (B, C, and D) compared with Stage A. These metabolites include flavin mononucleotide, l-methionine, muricatacin, amillaripin, 2-methylbutyroylcarnitine, lumichrome, hexadeconoic acid, and lysoPE (0:0/16:0). Conclusion: This study showed that the expressions of metabolites at different stages of CRC were different, which represent the metabolic changes occurring as CRC advances. The knowledge may help identify biomarkers for the staging of CRC, which could improve its prognosis as well as provide a basis for the development of therapeutic interventions. © 2019 The Authors. | |
700 | 1 | 0 | |a Ab-Rahim, S. |e author |
700 | 1 | 0 | |a Jamal A, R.A. |e author |
700 | 1 | 0 | |a Mazlan, M. |e author |
700 | 1 | 0 | |a Nathan, S. |e author |
700 | 1 | 0 | |a Ngah, W.Z.W. |e author |
700 | 1 | 0 | |a Yusof, H.M. |e author |
773 | |t International Journal of Applied Pharmaceutics |x 09757058 (ISSN) |g 11 Special Issue 5, 66-70 |